In this trial, patients with EGFR or ALK-positive NSCLC who were chemotherapy-naïve or had failed/intolerant prior TKI therapy received atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) versus bevacizumab + carboplatin + paclitaxel (BCP). The gene discussed is ALK; the disease is non-small cell lung carcinoma.